Since the outbreak of the new type of coronavirus pneumonia (COVID-19) in December 2019, the scientific community has been working fervently to develop treatments to combat the disease. Globally, scientists are exploring every potential weapon to suppress the global threat. Approaches under investigation include vaccines, medications, combination therapies, and perhaps most interestingly, living therapies with promising cell types such as natural killer (NK) cells, stem cells and exosomes. [Read more…]
Aspire Health Science Announces Strategic Partnership with NeoProgen for Development and Manufacturing of NeoProgen’s cell-based therapy
ORLANDO, Florida, May 6th, 2020– Aspire Health Science, LLC (the “Company” or “Aspire”), an FDA registered GMP manufacturing facility specialized in the research, development, and manufacturing of cell-based therapies, is pleased to announce a collaboration with NeoProgen, Inc.
NeoProgen, a Baltimore-based company led by Medtech entrepreneur Bill Niland, is a preclinical stage therapeutics company specializing in the development of novel cellbased cardiac therapies for heart regeneration. Similar to Mr. Niland’s earlier venture with Harpoon Medical, NeoProgen has origins in research at the University of Maryland, Baltimore. That is where Dr. Sunjay Kaushal, a leading pediatric cardiac surgeon, discovered that a specific kind of neonatal cardiac progenitor/ stem cells (nCPCs), obtained from discarded cardiac tissue biopsies, are extremely effective in regenerating muscle tissue in the heart. [Read more…]
Citius to License Novellus’ iPSC-derived MSCs for COVID-19 Related Complications
– Novellus’ patented mRNA-based cell-reprogramming technology creates MSCs with superior immunomodulatory properties
– Novellus’ iPSC-derived MSCs have manufacturing advantages over primary adult, donor-derived MSCs, allowing for larger supply, faster scale-up, and a more consistent cellular product
– MSCs may remedy the cytokine storm that triggers acute respiratory distress syndrome (ARDS) in COVID-19 patients
Stem Cell Researchers Use AI to Help Improve Regenerative Medicine
Medicine and technology can work together to produce amazing results. One of the most promising ‘marriages’ is that involving stem cell research and artificial intelligence (AI). Researchers are attempting to use AI to aid and augment stem cell technologies. How can machine learning play a role in restorative medicine? [Read more…]
Lattice Biologics Launches Phase 1 Coronavirus Trial in Seattle for AmnioBoost Stem Cell Therapy
Lattice Biologics is recruiting 10 patients for it Phase 1 clinical trial in Seattle to assess its novel stem cell therapy, AmnioBoost, for the treatment of COVID-19 lung disease.
BELGRADE, Mont. — Lattice Biologics Ltd. has begun enrolling patients in its Phase 1 clinical trial to address safety and efficacy of its novel stem cell technology, AmnioBoost, for the treatment of severe acute respiratory syndrome (SARS) related to COVID-19 infection. AmnioBoost is derived from amniotic fluid taken from non-related, healthy, living donors during a Caesarian delivery. The baby is not harmed in any way. [Read more…]
- « Previous Page
- 1
- …
- 100
- 101
- 102
- 103
- 104
- …
- 201
- Next Page »